SAI - Detailed view

Information for prof.

Leaflet

Report error

Nuvaxovid 5 ml, Injektionsdispersion 10

Drug

Nuvaxovid, Injektionsdispersion
Aktive Immunisierung zur Vorbeugung der durch das SARS-CoV-2-Virus verursachten Coronavirus-2019-Erkrankung (COVID-19) ab 12 Jahren
J07BX03 - COVID-19 VACCINES
08.08. – vaccines

HAM – Human medicine
DISIJ – dispersion for injection
I – vaccines
B – Dispensed on prescription by a physician or veterinarian (B)

B – limited
68473
4/12/2022
4/12/2024

Dosage strength

Nuvaxovid 5 ml, Injektionsdispersion
Aktive Immunisierung zur Vorbeugung der durch das SARS-CoV-2-Virus verursachten Coronavirus-2019-Erkrankung (COVID-19) ab 12 Jahren
01
B – limited

Package

No information made available
A/NR – Authorised / not referenced 

10 vial(s)

001
B – limited

Declaration

Component

5 µg SARS CoV-2 rS NVX-CoV2373
42.5 µg saponinum
7.5 µg saponinum
Quillaja saponariae Molina extractum purificatum
cholesterolum
phosphatidylcholinum
int-rac-alpha-tocopherolum
kalii dihydrogenophosphas
kalii chloridum
dinatrii phosphas dihydricus
dinatrii phosphas heptahydricus
natrii dihydrogenophosphas monohydricus
natrii chloridum
polysorbatum 80
natrii hydroxidum
acidum hydrochloridum
aqua ad iniectabile
4.0 mg natrium
0.003 mg kalium

Authorisation holder

7601001397088
Future Health Pharma GmbH
Guyer-Zeller-Strasse 10
8620 Wetzikon ZH (ZH)

Date of revision of the text

11/1/2022

Information for prof.

Leaflet

Report error

Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.